VEGFA and VEGFR2 Gene Polymorphisms and Response to Anti–Vascular Endothelial Growth Factor Therapy: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Individual variation in response and duration of anti-vascular endothelial growth factor (VEGF) therapy is seen among patients with neovascular age-related macular degeneration. Identification of genetic markers that affect clinical response may result in optimization of anti-VEGF therapy. OBJECTIVE: To evaluate the pharmacogenetic relationship between genotypes of single-nucleotide polymorphisms (SNPs) in the VEGF signaling pathway and response to treatment with ranibizumab or bevacizumab for neovascular age-related macular degeneration. DESIGN, SETTING, AND PARTICIPANTS: In total, 835 of 1149 patients (72.7%) participating in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) at 43 CATT clinical centers. INTERVENTION: Each patient was genotyped for 7 SNPs in VEGFA (rs699946, rs699947, rs833069, rs833070, rs1413711, rs2010963, and rs2146323) and 1 SNP in VEGFR2 (rs2071559) using TaqMan SNP genotyping assays. MAIN OUTCOMES AND MEASURES: Genotypic frequencies were compared with clinical measures of response to therapy at 1 year, including the mean visual acuity, mean change in visual acuity, at least a 15-letter increase, retinal thickness, mean change in total foveal thickness, presence of fluid on optical coherence tomography, presence of leakage on fluorescein angiography, mean change in lesion size, and mean number of injections administered. Differences in response by genotype were evaluated with tests of linear trend calculated from logistic regression models for categorical outcomes and linear regression models for continuous outcomes. The method of controlling the false discovery rate was used to adjust for multiple comparisons. RESULTS: For each of the measures of visual acuity evaluated, no association was observed with any of the genotypes or with the number of risk alleles. Four VEGFA SNPs demonstrated an association with retinal thickness: rs699947 (P = .03), rs833070 (P = .04), rs1413711 (P = .045), and rs2146323 (P = .006). However, adjusted P values for these associations were all statistically nonsignificant (range, P = .24 to P = .45). Among the participants in 2 as-needed groups, no association was found in the number of injections among the different genotypes or for the total number of risk alleles. The effect of risk alleles on each clinical measure did not differ by treatment group, drug, or dosing regimen (P > .01 for all). CONCLUSIONS AND RELEVANCE: This study provides evidence that no pharmacogenetic associations exist between the studied VEGFA and VEGFR2 SNPs and response to anti-VEGF therapy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00593450.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Self-citationHaines, J. L., Schnetz-Boutaud, N., Schmidt, S., Scott, W. K., Agarwal, A., Postel, E. A., Olson, L., Kenealy, S. J., Hauser, M., Gilbert, J. R., et al. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0116 · Cited by 189
Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Callanan, D. G., Kim, I. K., Klein, M. L., Maguire, M. G., & Martin, D. F. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.037 · Cited by 142
Self-citationGenetic association with response to intravitreal ranibizumab in patients with neovascular AMD
Kloeckener-Gruissem, B., Barthelmes, D., Labs, S., Schindler, C., Kurz-Levin, M., Michels, S., Fleischhauer, J., Berger, W., Sutter, F., & Menghini, M. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6080 · Cited by 120
McKibbin, M., Ali, M., Bansal, S., Baxter, P. D., West, K., Williams, G., Cassidy, F., & Inglehearn, C. F. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.193680 · Cited by 100
Lotery, A. J., Gibson, J., Cree, A. J., Downes, S. M., Harding, S. P., Rogers, C. A., Reeves, B. C., Ennis, S., & Chakravarthy, U. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.07.046 · Cited by 64
Cited by
A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration
Schmidt-Erfurth, U., & Waldstein, S. M. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.007 · Cited by 390
“However, other reports failed to replicate these findings (Hagstrom et al., 2013, 2014; Park et al., 2014).”
ResultMettu, P. S., Allingham, M. J., & Cousins, S. W. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100906 · Cited by 370
Genetics and genetic testing for age-related macular degeneration
Warwick, A., & Lotery, A. (2018) · Eye · doi:10.1038/eye.2017.245 · Cited by 67
Wu, M., Xiong, H., Xu, Y., Xiong, X., Zou, H., Zheng, M., Wang, X., & Zhou, X. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309418 · Cited by 36
Hagstrom, S. A., Ying, G.-S., Maguire, M. G., Martin, D. F., Gibson, J., Lotery, A., & Chakravarthy, U. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.04.024 · Cited by 37
Self-citation
Metadata
- Authors
- Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Maguire, M. G., & Martin, D. F.
- Venue
- JAMA Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2014-05-01
- Volume
- 132
- Issue
- 5
- Pages
- 521
- ISSN
- 2168-6165 (ISSN-L)
- OpenAlex
- W2135240714
- Cited by
- 62
- References
- 11
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: VEGFA and VEGFR2 Gene Polymorphisms and Response to Anti–Vascular Endothelial Growth Factor Therapy: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). https://app.cochat.ai/papers/10.1001/jamaophthalmol.2014.109
- The paper
- Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Maguire, M. G., & Martin, D. F. (2014). VEGFA and VEGFR2 Gene Polymorphisms and Response to Anti–Vascular Endothelial Growth Factor Therapy: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). JAMA Ophthalmology. https://doi.org/10.1001/jamaophthalmol.2014.109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.